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ABSTRACT 
Significance: Reactive oxygen species (ROS) such as superoxide, hydrogen peroxide and 
peroxynitrite are generated ubiquitously by all mammalian cells and have been understood for 
many decades to inflict cell damage and to cause cancer by oxidation and nitration of 
macromolecules including DNA, RNA, proteins and lipids. Recent advances: A current 
concept suggests that ROS can also promote cell signaling pathways triggered by growth 
factors and transcription factors that ultimately regulate cell proliferation, differentiation and 
apoptosis, all of which are important hallmarks of tumor cell proliferation and angiogenesis.  
Moreover, an emerging concept indicates that ROS regulate the functions of immune cells 
that infiltrate the tumor environment and stimulate angiogenesis, such as macrophages and 
specific regulatory T cells. Critical Issues: In this review, we highlight that the NADPH 
oxidase family of ROS-generating enzymes are the key sources of ROS and thus play an 
important role in redox signaling within tumor, endothelial and immune cells to thereby 
promote tumor angiogenesis. Future Directions: Knowledge of these intricate ROS signaling 
pathways and identification of the culprit NADPH oxidases is likely to reveal novel 
therapeutic opportunities to prevent angiogenesis that occurs during cancer and which is 
responsible for the revascularization following current anti-angiogenic treatment.  
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INTRODUCTION: THE NEED TO UNDERSTAND NADPH OXIDASE-DEPENDENT 
SIGNALING IN CANCER 
A substantial body of evidence indicates that one of the most important hallmarks of 
cancer is the chronic induction of angiogenesis - the process of new blood vessel formation 
(78, 79). This process allows solid tumors to grow beyond a few millimetres in diameter and 
then to metastasize and spread to distant sites. Therefore, there has been a keen interest in 
developing drugs to target angiogenesis for cancer therapy. The knowledge that pro-
angiogenic growth factors such as vascular endothelial growth factor (VEGF) are released 
from tumors and activate endothelial progenitors and vascular endothelial cells to proliferate 
and form neovasculature has given rise to the current inhibitors of angiogenesis (VEGF 
receptor blockers). Despite displaying some efficacy against cancers in both animal models (1) 
and in humans (54), the benefits of these compounds are short-lived with revascularization 
occurring, and initially responsive tumors progressing (18). Thus, there is a need for new 
drugs with sustained anti-angiogenic properties.  
Two new paradigms in cancer research have emerged with tremendous potential to 
give rise to novel therapeutic strategies. The first proposes a novel role for reactive oxygen 
species (ROS) as a stimulus for tumor angiogenesis. The second suggests that angiogenesis 
and the revascularization following conventional anti-angiogenic drug therapy, is caused by 
chronic inflammation (18, 33, 127). ROS such as superoxide, hydrogen peroxide (H2O2), 
peroxynitrite (OONO
-
) and hydroxyl radical (OH
.
) have been traditionally implicated in 
cancer as they can induce DNA damage and mutations, RNA alkylation, lipid peroxidation 
and protein damage and dysregulation (85). However, in addition to these direct cytotoxic and 
mutagenic effects, more recent evidence indicates that ROS are important regulators of signal-
transduction pathways that promote angiogenesis and tumorigenesis. In this review, we will 
highlight the NADPH oxidase family of ROS-generating enzymes as key sources of ROS that 
Page 3 of 57 
A
nt
io
xi
da
nt
s &
 R
ed
ox
 S
ig
na
lin
g
N
A
D
PH
 O
X
ID
A
SE
S 
A
S 
RE
G
U
LA
TO
RS
 O
F 
TU
M
O
R 
A
N
G
IO
G
EN
ES
IS
: C
U
RR
EN
T 
A
N
D
 E
M
ER
G
IN
G
 C
O
N
CE
PT
S.
 (d
oi:
 10
.10
89
/ar
s.2
01
1.4
48
9)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
4 
 4 
influence many facets of cell signaling during cell proliferation and apoptosis. Finally, we 
will draw attention to the novel concept that NADPH oxidase-derived ROS are crucial 
regulators of tumor anti-immunity via effects on specialized subsets of immune cells such as 
macrophages and T lymphocytes and that they could represent a novel molecular link 
between chronic inflammation and angiogenesis during cancer. 
 
GENERAL FEATURES OF ROS 
For many years ROS have been considered as by-products of aerobic respiration and 
mediators of a number of critical cellular functions such as the killing of pathogens. However, 
more recently ROS have been acknowledged as important signaling intermediates in 
processes such as cell proliferation, migration, differentiation and apoptosis. ROS are highly 
reactive oxygen-containing molecules occurring in both radical and non-radical forms. 
Superoxide, often considered the parent species of the ROS family of molecules, is produced 
during oxygen metabolism as a result of the one-electron reduction of molecular oxygen 
(Figure 1). The high reactivity of superoxide is due to the instability of an unpaired electron in 
its valence shell. Superoxide has been implicated in numerous pathological processes 
including cancer, cardiovascular disease (e.g. atherosclerosis and stroke) and acute and 
chronic diseases caused by microbial infections. Superoxide can directly damage DNA 
through oxidation (95), directly inactivate cellular antioxidants such as catalase and 
glutathione peroxidase (157), and induce cellular accumulation of sorbitol as well as activate 
pro-inflammatory NF-κB (143). However, superoxide gives rise to additional ROS that 
possess different redox chemistries, and thus different physiological and pathophysiological 
effects. For example, superoxide is rapidly reduced, both spontaneously (59) and 
enzymatically (135) to give rise to H2O2 (Figure 1). Unlike superoxide, H2O2 has no net 
charge so, apart from being an efficient oxidant it is more lipid-soluble, with the potential to 
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diffuse through organelles and cellular membranes to sites distant from its production (144). 
Hydrogen peroxide modifies (1) cellular proteins via oxidation of sulphur-containing amino 
acids, cysteine and methionine (138, 156), (2) lipids by peroxidation (94) and (3) genetic 
material (i.e. RNA and DNA) (82). These oxidative processes have been implicated in many 
diseases in addition to cancer including Alzheimer’s (137) and Parkinson’s disease (122). 
However, perhaps the major detrimental properties of H2O2, like superoxide, are in its ability 
to give rise to more reactive molecules. For instance, H2O2 can be reduced by transition 
metals, namely ferrous iron, with or without superoxide to form the highly reactive hydroxyl 
radical (OH
.
; Figure 1) (100). The pathological formation of hydroxyl from H2O2 is a very 
important biological reaction. The hydroxyl radical is highly reactive and will 
indiscriminately oxidize the nucleotides of cellular DNA to cause breaks and lesions (for 
review see (25, 173)) which are processes linked to carcinogenesis (126). The oxidation of 
lipids by hydroxyl radical may influence many physiological processes and contribute to 
cellular dysfunction during cardiovascular disease (175). 
Arguably one of the most important redox reactions occurring in biology is that 
between superoxide and the nitric oxide (NO) radical. With a reaction rate of ~10
10 
MS
-1
 it is 
one of the fastest reactions in biology giving rise to peroxynitrite (ONOO
−
; Figure 1) (84). 
Peroxynitrite is an oxidising and nitrating agent that has been implicated in cancer (58) and 
other acute (99) and chronic (184) diseases. Through oxidation of cysteine and transition 
metal-containing proteins and nitration of tyrosine, peroxynitrite can influence the 
physiological properties of many proteins including haemoglobin, myoglobin, cytochrome c, 
inducible nitric oxide synthase (iNOS), endothelial NOS (eNOS), mitochondrial aconitase, 
phosphogluconate dehydratase, alcohol dehydrogenase, complexes I, II, III and IV of the 
electron transport chain and elicit changes in protein structure through thiol oxidation (147). 
In the artery wall, this reaction between superoxide and NO holds major biological 
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significance. First identified in 1987 (148), NO is regarded as one of the most important 
vascular signaling molecules owing predominantly but not exclusively to its properties as a 
vasorelaxant, anti-inflammatory and anti-thrombotic agent. The reaction of superoxide with 
vascular NO leads to endothelial dysfunction and vascular inflammation giving rise to 
hypertension (74) and atherosclerosis (197).  
 
SOURCES OF ROS: NADPH OXIDASE FAMILY OF ENZYMES 
Several enzymes produce superoxide and other ROS, including the mitochondrial 
electron transport chain, NOS, cytochrome P450 reductase and xanthine oxidase. However, for 
all of these systems, superoxide production occurs as a by-product of another reaction that 
represents the main catalytic function of the enzyme/system or from a dysfunctional variant of 
the enzyme. In contrast, NADPH oxidases are the only enzymes whose primary function is to 
generate superoxide/ROS. NADPH oxidases are multi-subunit enzyme complexes highly 
conserved across a vast array of organisms (106) with significant homology among higher 
order mammals (29). The family is comprised of 7 oxidases, named Nox1, Nox2, Nox3, Nox4, 
Nox5, Duox1 and Duox2 (50, 166). 
 
General features of Nox subunits 
The Nox-containing NADPH oxidases (Nox1-5) are highly proficient ROS-generating 
enzymes with a wide distribution among human tissues (103). The catalytic Nox protein 
contains six hydrophobic transmembrane domains and a long intracellular C-terminus tail. 
The transmembrane domains contain four conserved histidine residues, which bind heme 
groups believed to be essential for electron transfer across the plasma membrane (20). The 
electrons utilized by the oxidase are donated from the oxidation of NADPH or NADH. The 
cytosolic C-terminus contains putative NADPH binding sites which transfers electrons from 
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NADPH to a flavin adenine dinucleotide (FAD) bound at the N-terminus end of the cytosolic 
tail (77, 116). The electrons are then transferred through the heme groups to reduce molecular 
oxygen, forming superoxide or H2O2, depending on the Nox isoform. 
In addition to the catalytic Nox protein, Nox1-4 require a number of other regulatory 
proteins which are important for enzyme localization, stability and activation, including 
p22phox, p47phox, p67phox, p40phox and Rac (145) (Figure 2). Nox5 does not require 
interaction with other regulatory proteins but is regulated by calcium. Although the Duox 
proteins have been shown to interact with p22phox, the activity of the enzymes are not 
influenced by this interaction and it remains unclear whether additional proteins are required 
for activation (194). 
 In the following sections we provide a brief review of some key structural features of 
each of the Nox oxidases and their respective regulatory subunits (Figure 2). For a more 
comprehensive description we refer you to the following recent reviews (115, 165).  
 
NADPH oxidase 2 (Nox2 oxidase) 
The Nox2 subunit is bound within cellular membranes including plasma and endoplasmic 
reticulum to a second protein, p22phox, in a heterodimer named cytochrome b-558 (149). The 
stable expression of a mature Nox2 and the activity of the Nox2 oxidase is dependent on 
p22phox co-expression (93, 149) with Nox2 monomer rapidly targeted for degradation by 
cytosolic proteasomes in p22phox deficiency (42). In addition to cytochrome b-558 
stabilisation, the C-terminus of p22phox contains a region of high proline content that 
interacts with a Src homology 3 (SH3) domain of the organizer protein p47phox; a process 
which is essential for oxidase activation (114). p47phox is a cytosolic protein which 
translocates upon stimulation to the membrane bound cytochrome b-558 heterodimer. The 
p47phox protein has two regions with significant SH3 homology, one of which is bound to an 
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upstream proline-rich region of the protein under basal conditions. In response to 
phosphorylation of a number of serine residues on p47phox, the SH3 domains become 
exposed allowing interaction of the first SH3 domain with the p22phox proline-rich region 
(56). Additionally p47phox can interact with at least two other binding sites on the Nox2 
protein (44). p47phox is essential for the recruitment of another cytosolic protein p67phox to 
the cytochrome b-558 complex (81). p47phox interacts with p67phox via the second SH3 
domain (40). Upon translocation to the membrane, p67phox directly interacts with Nox2 via 
an activation domain (76) and binds a small GTPase, Rac (47). Finally, p40phox interacts 
with the Nox2 complex via binding domains on p47phox and p67phox, and although it has 
been shown to promote Nox2 oxidase activity it is not considered an essential regulator (4, 
60). Nox2 oxidases are ubiquitously expressed in mammalian cells. They are highly expressed 
in inflammatory cells such as macrophages, and are readily detected in endothelial cells. 
 
Nox1 oxidase 
Almost 25 years after the discovery of NADPH oxidases in phagocytic cells, the first 
homologue of the gp91phox subunit of the prototypical phagocytic oxidase was identified and 
termed Mox1 (for mitogen oxidase 1) (178). Later renamed Nox1, this protein shares 56% 
homology with Nox2 and is similar in many respects, structurally to Nox2. The structural 
similarities between Nox1 and Nox2 include the C-terminal cytoplasmic tail containing the 
NADPH binding sites, FAD moieties and 2 heme regions as well as 6 putative transmembrane 
spanning regions. Like Nox2, Nox1 is complexed and stabilised with p22phox at the protein 
level (7, 93) and is tightly and efficiently regulated by several modulatory protein subunits. 
Indeed, Nox1–p22phox heterodimers are relatively inactive but produce superoxide in the 
presence of NoxO1 (Nox organiser 1) and NoxA1 (Nox activator 1), which are homologous 
to p47phox and p67phox, respectively (6, 12, 67). It is noteworthy that both p47phox and 
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p67phox are capable of stimulating superoxide production in Nox1-expressing systems and 
but not as efficiently as NoxO1 and NoxA1 (6, 67). Nox1 is expressed in colon and airway 
epithelium, stomach uterus, as well as vascular smooth muscle cells (12, 29, 178). 
 
Nox3 oxidase 
Nox3 was first described about 10 years ago based on its sequence similarity to other Nox 
isoforms (96). Its overall structure is similar to that of Nox1 and Nox2, in terms of 
transmembrane domains, the length of the extracellular loops, NADPH- and FAD-binding 
sites, and the localization of the heme-coordinating histidines (29, 96). Nox3 is also 
dependent on p22phox
 
for its stabilization, plasma membrane localization and activation 
(185). Activation of Nox3 occurs in the presence of NoxO1 and NoxA1, although some 
evidence is contradictory. In heterologous expression studies, p47phox and p67phox are 
capable of activating Nox3 (13, 185, 186); however, the physiological relevance of this is 
unknown. The dependence of Nox3 on Rac is also still a matter of debate. Overall the Nox3 
oxidase is constitutively active and its tissue distribution, as determined by real time PCR and 
in situ hybridization, demonstrates a very high expression in the inner ear, including the 
cochlear and vestibular sensory epithelia and the spiral ganglion (13). Low levels of Nox3 can 
also be detected in other tissues, including fetal spleen (96), fetal kidney (13, 29) skull bone, 
and brain (13).  
 
Nox4 oxidase 
First identified in kidney and initially termed ‘Renox’ (66, 169), Nox4 shares 39% homology 
with Nox2 and possesses the same conduit of electron transporting moieties as Nox1 and 
Nox2, including the NADPH binding site, FAD and heme groups. Like Nox1 and Nox2, the 
prototypical, full size Nox4 forms a heterodimer with p22phox, which is necessary for its 
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activity and stability (7, 131). However, unlike Nox1 and Nox2, the PRR region of p22phox 
is not necessary for Nox4 oxidase activity (93). Thus, the additional molecular interactions 
that p22phox makes with organiser proteins like p47phox and NoxO1 are not crucial for Nox4 
oxidase-dependent ROS production (93). As a consequence, Nox4 may serve as an important 
constitutively active ROS-generating system, whose overall ROS output is governed by its 
expression level (200), post-translational modification and via its interactions with the 
polymerase -interacting protein 2 (POLDIP2) (123). Contrary to Nox1, Nox2, Nox3 and 
Nox5, Nox4 activity results in the release of H2O2 rather than superoxide (181). This is most 
probably owing to a delayed dissociation of superoxide from the catalytic subunit due to 
hindrance by the third extracytoplasmic loop, allowing time for a second molecule of 
superoxide to be formed and to be consequently dismutated before being released from the 
enzyme (181). Nox4 is expressed in kidney cortex in high amounts as well as endothelial cells, 
smooth muscle cells, heart, pancreas and osteoclasts but not in phagocytic cells (for review 
see (50, 165). 
 
Nox5 oxidase 
Nox5 contains a unique, cytosolic N-terminal Ca
2+
 binding domain with calmodulin-like EF-
hand motifs that render this oxidase highly sensitive to Ca
2+
 (14) and to phosphorylation that 
increases Ca
2+
 sensitivity (88). However, it also possesses the same redox centres and 
NADPH binding sites as Nox1 to Nox4. Nox5 displays only ∼22–27% homology to Nox1 
through to Nox4 (14), but unlike those Nox proteins, it does not require p22phox for 
activation (93) nor any of the other known regulatory subunits. Interestingly, there are five 
splice variants identified to date, named Nox5α, Nox5β, Nox5γ, Nox5δ and Nox5s, that differ 
in the sequence of their Ca
2+
 binding regions as well as their tissue distribution (16). Nox5s 
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lacks the Ca
2+
 binding regions and is constitutively active (16). Nox5 is expressed in human 
lymphoid tissues, testis and spleen (14) and in endothelial cells (16). 
 
Dual oxidase (Duox)  
Duox1 and 2 are dual property enzymes, which comprise a catalytic protein containing an N-
terminus peroxidase domain and a C-terminus NADPH oxidase region. They are largely 
localized to the thyroid gland and lung epithelial cells of adults where they are thought to be 
involved in hormone biosynthesis and host defence through the production of H2O2 by the 
NADPH oxidase domain (39, 51, 68). The role of the peroxidase region of the Duox is not 
well understood but has been shown to promote tyrosine-dependent cross linking of structural 
proteins in C. elegans (49). 
 
CELLULAR LOCALIZATION AND FUNCTIONS OF NADPH OXIDASES IN THE 
TUMOR ENVIRONMENT 
ROS-generating cells relevant to tumor development and progression, but not strictly 
limited to angiogenesis, include: tumor cells, endothelial cells (of both blood and lymphatic 
vessels) and immune cells such as macrophages and T lymphocytes that infiltrate the tumor 
environment. In the following section we provide a summary of the current state of 
knowledge of Nox oxidase expression and activity in tumor and endothelial cells, and the cell 
signaling mechanisms they regulate to influence proliferation, apoptosis and angiogenesis 
during cancer (Figure 3). In the last section on “Emerging concepts” we will put forward 
novel ideas on Nox-dependent regulation of lymphangiogenesis, and of immune cell function, 
particularly of macrophages and immunoregulatory T lymphocytes.  
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Tumor cells: NADPH oxidase-derived ROS regulate autocrine and paracrine effects 
Nox1, Nox2 and Nox4 are known to be expressed in multiple tumor cell types. For example, 
Nox1 is highly expressed in human colon cancer cells (110) and prostate cancers (119). Nox4 
is expressed in human gliomas (170), melanomas (23), pancreatic adenocarcinomas (192), 
renal cell carcinomas (130) and ovarian cancer cells (202). Nox2 is expressed in myeloid 
leukemia cells and prostate cancer cells (118). Tumor cells produce substantial amounts of 
ROS (11, 75, 178, 179) via NADPH oxidases that possess autocrine effects, such as 
promoting their own proliferation, most likely through regulation of proliferative signaling 
kinases such as extracellular-signal-regulated kinases (ERK)-1/2 and cell survival factors like 
Akt. Also, Nox1-dependent ROS production critically mediates the effects of the oncogene 
Ras, in particular in the Ras dependent upregulation of VEGF that occurs via the Raf-MEK-
ERK pathway (98). Moreover, Nox1-dependent superoxide production occurring in tumor 
cells may activate Src and thereby stimulate downstream phosphatidylinositol 3-kinases 
(PI3K) and ERK-dependent survival pathways in response to angiopoietin-like-protein 4 
(ANGPTL4) that confers resistance to anoikis (212). 
Although ROS generated by tumor cells are likely to act in an autocrine fashion to 
influence cell proliferation/survival and other cellular processes, ROS have also been shown 
to regulate the release and actions of tumor-derived growth factors that induce endothelial cell 
proliferation leading to angiogenesis. For instance, ROS production within tumor cells 
dramatically promotes release of paracrine growth factors such as VEGF, which in turn 
stimulate proliferation, migration and tube formation in nearby endothelial cells. Indeed, ROS 
were found to increase VEGF expression in tumor cells and to also promote the expression of 
its receptor, VEGF receptor-1 (VEGFR-1) (8). In PC-3 prostate cancer cells, NADPH 
oxidase-derived ROS stimulates hypoxia inducible factor (HIF)-1 which in turn promotes 
the release of VEGF-A and subsequent angiogenesis. Thus, given that tumor-derived ROS are 
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an important trigger of angiogenesis, identifying the source of ROS in tumors under these 
circumstances may reveal novel targets to suppress ROS production for anti-angiogenesis 
therapy. In addition, NADPH oxidase expressed within endothelial cells is crucial for the 
ability of growth factors such as VEGF released by tumors to stimulate endothelial cell 
proliferation and consequently angiogenesis.  
 
Endothelial cells: NADPH oxidases in cell proliferation and apoptosis  
It has been known for some time now that ROS, including H2O2 and superoxide, can 
function as signaling molecules in vascular endothelial cells (189). Endothelial ROS are 
produced upon stimulation by growth factors such as VEGF, transforming growth factor- 
(TGF- fibroblast growth factors and angiopoietin-1, cytokines (i.e. tumor necrosis factor-; 
TNF-), fluid shear stress, ischemia–reperfusion, and leukocyte adhesion (83, 108, 132, 205). 
In endothelial cells, the Nox catalytic subunits Nox1, Nox2, Nox4, Nox5, and regulatory 
subunits Rac1, p47phox, p67phox and p22phox are expressed at the mRNA and protein level 
to varying degrees and with species variability. Ago et al., (2004) and Pendyala et al (2009) 
showed that the mRNA expression level of Nox4 was markedly higher than Nox1, Nox2 and 
Nox5 in human pulmonary artery endothelial cells, human lung microvascular endothelial 
cells and cultured human umbilical vein endothelial cells (5, 24, 150). In human endothelial 
cells, Nox5 is highly expressed and appears to represent a quantitatively relevant source of 
ROS in these cells. However, Nox5 is not expressed in rodent tissues.  
Evidence supporting a role for ROS produced by NADPH oxidase in the proliferation 
of endothelial cells came from studies that showed expression of p22phox, which is essential 
for the activities of Nox1, Nox2 and Nox4 was substantially higher in proliferating 
endothelial cells than in quiescent cells (15). Furthermore, transfection of cells with antisense 
for p22phox dramatically reduced both ROS production and cell proliferation (15). Evidence 
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for Nox isoform-specific effects on endothelial cell proliferation has come predominantly 
from siRNA experiments. Knockdown of Nox4 with siRNA attenuated hyperoxia-induced 
cell migration and capillary tube formation, suggesting that ROS generated by this NADPH 
oxidase isoform regulates endothelial cell motility and their migration (150). Furthermore, 
overexpression of Nox4 in endothelial cells increases ROS production and stimulates cell 
proliferation, whereas siRNA silencing of Nox4 has the opposite effect (38, 151, 152, 164) . 
Nox2 is a critical source of ROS in endothelial cells and an important regulator of 
their function (28, 73). In humans, the genetic deficiency of Nox2 (i.e. in chronic 
granulomatous disease (CGD) patients) is associated with enhanced endothelium-dependent 
flow-mediated vasorelaxation and decreased markers of vascular aging and oxidative stress by 
limiting nitric oxide availability (193). Using isolated vessels from wild-type and Nox2-
deficient mice, it has been demonstrated that superoxide formed by endothelial Nox2-
containing NADPH oxidase mediates endothelial dysfunction in renovascular hypertension by 
scavenging endothelium-derived NO (91). Moreover, endothelial Nox2 underpins vascular 
oxidative stress and contributes to early atherosclerotic plaque formation in the 
hypercholesterolemic mouse model of atherosclerosis (90). Thus, Nox2 has a dual function in 
the vasculature where it is involved in normal physiological signal transduction, but also in 
generation of pathological levels of ROS, which contribute to oxidative stress in various 
cardiovascular diseases (50, 166).  Nox2 is also involved in endothelial cell proliferation, as 
knockdown of Nox2 with siRNA affects endothelial cell morphology and is necessary for cell 
survival (86, 151). Nox2 also tethers with actin cytoskeleton via IQGAP1 at the leading edge 
of endothelial cells to direct ROS production and their migration (86). Rac1, which regulates 
Nox2 activity (but not Nox4 activity), is localized at the leading edge in wound-induced 
migrating cells (104) and endogenous H2O2 accumulates at the membrane ruffles in actively 
migrating endothelial cells (86). Overexpression of the active (GTP-bound) form of Rac1 
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induces loss of cell–cell adhesion (191) and cytoskeletal reorganization in primary human 
endothelial cells (139) through increased H2O2 production, which are required for endothelial 
cell migration. In addition to Rac1, during directed cell migration, p47phox translocates from 
the perinucleus to the membrane and to the leading edge or focal complexes through binding 
in endothelial cells (201). 
Nox1 also plays an important role in endothelial cell proliferation, sprouting and 
migration (64), whereas in sinusoidal endothelial cells, Nox1 regulates apoptosis (97). Nox5 
variants were found to be actively involved in the generation of ROS, proliferation and 
formation of capillary-like structures in human microvascular endothelial cells (16), however, 
much less is known about the role of Nox5 in general, largely due to the fact that Nox5 is not 
found in rodents (92). 
 
CELL SIGNALING MECHANISMS AND PATHWAYS INFLUENCED BY NADPH 
OXIDASE-DERIVED ROS 
Proliferative kinases 
Under physiological conditions, Nox2 and Nox4 are important intermediates in signal 
transduction pathways regulating the activities of a large panel of growth factors, cytokines 
and hormones. As both Nox2 and Nox4 regulate endothelial cell proliferation, it is the 
specific localisation of these enzymes that is likely to be critical for their respective roles in 
activation of cellular signaling pathways. The association of Nox2 and its regulatory subunits 
p47phox, p67phox and p22phox to the cytoskeleton can affect the re-arrangement of the 
endothelial cytoskeleton during cell proliferation and migration (3, 86). In contrast to Nox2, 
localisation of Nox4 to the peri-nuclear and endoplasmic reticulum membranes (5, 24, 71) 
could conceivably result in activation of kinases such as mitogen-activated protein kinase 
(MAPK) and Src to promote cell proliferation.  
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MAPK families play an important role in complex cellular functions like proliferation, 
differentiation, development, transformation and apoptosis. At least three MAPK families 
have been characterized: ERK, Jun kinase/stress-activated protein kinase (JNK/SAPK) and 
p38 MAPK (reviewed in (211)). ERK1 and ERK2 regulate endothelial cell proliferation and 
migration during mouse embryonic angiogenesis (174). Furthermore, MAPK regulates many 
aspects of adult endothelial cell activation including survival (62, 206), proliferation and 
migration (31). Buul et al (2005) found that on endothelial monolayers, Rac mediates ROS 
production via Nox2 and thus leads to the activation of p38 MAP kinase and loss of 
monolayer integrity through the inactivation of VE-cadherin-mediated cell–cell adhesion (24). 
Similarly, this pathway is also activated following leukocyte adhesion, and it is important for 
efficient leukocyte transendothelial migration. Conversely, in isolated or freshly-seeded 
endothelial cells, ROS are required for spreading and formation of cell–cell contact (24). This 
latter finding may be partially explained by inefficient inactivation of Rho, for which ROS are 
also required (142). Peshavariya et al (2009) showed that Nox2 oxidase-dependent superoxide 
production is anti-apoptotic by regulating the morphology of the cytoskeleton in an Akt-
dependent manner (151). Basal Nox4 oxidase-dependent ROS alters the activity of MAPK 
(24, 71, 89, 136, 152) and Nox4 overexpression and formation of an active complex with 
p22phox enhances superoxide formation and phosphorylation of p38 MAPK(71) in 
endothelial cells. Furthermore, ROS, most likely H2O2, are generated by Nox4 via the 
activation of ERK1/2 and Akt (151). In addition, activation of p38 MAPK has been also 
implicated in induction of cell apoptosis via Nox4 activity (188). 
The tyrosine kinase Src plays an important role in hyperoxia-induced tyrosine 
phosphorylation of p47phox and NADPH oxidase activation in human pulmonary artery 
endothelial cells (30). The ERK and p38 MAPK pathways also contribute to NADPH oxidase 
activation in these cells (71, 89). ROS are important for VEGF-induced Src activation and 
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Akt, contributing to the stimulation of angiogenesis in endothelial cells (120, 190). It is 
therefore clear that ROS, derived from the activities of Nox2 and Nox4, play important roles 
in the activation of a number of endothelial cell signaling pathways, and as such are likely to 
be major contributors to tumor angiogenesis.  
 
Angiogenic growth factors and transcription factors 
ROS are important players in cancer biology (121). In tumor endothelial cells, Nox 
enzymes contribute to angiogenesis through ROS-dependent mechanisms as described above, 
and thereby promote tumor growth via activation of signaling pathways. A number of 
transcription factors and genes involved in tumor angiogenesis are regulated by ROS, 
including VEGF-A, HIF-1, p53, and matrix metalloproteinases (MMPs). 
 
VEGF: The mitogenic and chemotactic effects of VEGF-A in endothelial cells are mediated 
mainly through VEGFR-2, which is activated through autophosphorylation of tyrosine 
residues in the cytoplasmic kinase domain (172). This event is followed by activation of 
downstream signaling pathways such as MAPK, Akt and eNOS, which are essential for 
endothelial cell migration and proliferation (107). VEGF-A stimulation increases ROS 
production via activation of Rac1-dependent NADPH oxidase in endothelial cells (190, 204, 
213). Zhuang et al (2010) found that overexpression of Nox4 significantly enhances VEGF-
A-induced ROS generation and cell adhesion molecules in endothelial cells (213).  
 
HIF-1: High expression levels of the transcription factor HIF-1 are observed in many human 
cancers (63, 134, 203). In addition to modulating factors involved in angiogenesis, HIF-1 
activates the transcription of many genes involved in other aspects of tumor growth including 
cancer cell survival and invasion (37, 63, 134), and its levels correlate with tumorigenesis 
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(134). In response to tumor hypoxia, HIF-1 up-regulates a number key angiogenesis-related 
genes including VEGF-A and erythropoietin (117, 195). The Rac1/Nox/ROS pathway plays 
an important role for up-regulation of HIF-1 and VEGF-A expression in response to hypoxia 
(61).  These reports suggest that ROS play an important role in upregulation of HIF-1 protein 
expression, which in turn contributes to upregulated VEGF-A expression and subsequent 
tumor angiogenesis. 
 
p53: p53 is an important intracellular mediator of the stress response, including that initiated 
by ROS, and is now also recognized as a modifier of the angiogenic response. Salmeen et al 
(2010) found that ROS derived from Nox2 (but not Nox4) are functionally involved in the 
regulation of the cell cycle inhibitors p21
cip1
 and p53 and participate in endothelial cell cycle 
regulation and apoptosis (160). p53 interacts with the HIF system and Nox, but also has direct 
effects on angiogenesis regulators by interfering with translation mechanisms of angiogenesis 
factors and mediators such as VEGF-A (210) .  
 
MMPs: MMPs are another family of enzymes involved in the progression of tumor-induced 
angiogenesis whose activities are regulated by ROS (146). MMPs regulate endothelial cell 
ingression into the tumor tissue by degrading extracellular matrix and freeing the way for 
migrating endothelial cells (69). ROS can activate MMP-10 via VEGF-A (80). Furthermore, 
VEGF-A and NO stimulate MMP-1 and 2 expression in endothelial cells (69). A recent study 
showed that the pro-inflammatory cytokine TNF-, stimulates H2O2 production that promotes 
p38 MAP kinase and MMP-9 activation as well as sprouting angiogenesis in endothelial cells 
most likely via activation of Nox2 (154).  
 
A
nt
io
xi
da
nt
s &
 R
ed
ox
 S
ig
na
lin
g
N
A
D
PH
 O
X
ID
A
SE
S 
A
S 
RE
G
U
LA
TO
RS
 O
F 
TU
M
O
R 
A
N
G
IO
G
EN
ES
IS
: C
U
RR
EN
T 
A
N
D
 E
M
ER
G
IN
G
 C
O
N
CE
PT
S.
 (d
oi:
 10
.10
89
/ar
s.2
01
1.4
48
9)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
19 
 19 
STUDIES IN TRANSGENIC AND KNOCKOUT MICE SHOW PROMISE BUT IN 
VIVO EVIDENCE IS STILL LACKING 
Our review of the literature above is in line with the notion that ROS derived from 
NADPH oxidase play an important role in VEGF-A signaling linked to angiogenesis in 
endothelial cells. NADPH oxidase appears to be localized within discrete subcellular 
compartments, thereby activating specific redox signaling pathways. These events could be 
regulated by VEGF, HIF-1, p53 or MMPs, which contribute to temporal and spatial 
organization of ROS-dependent VEGF-A signaling linked to angiogenesis in endothelial cells. 
However, despite considerable amount of in vitro evidence that Nox oxidases expressed in 
endothelial cells are likely to influence tumor angiogenesis, close inspection of the literature 
reveals that there is still very little evidence to support this in vivo using tumor mouse models 
and key cell-specific Nox knockout mice. In fact, to the best of our knowledge the recent 
study by Garrido-Urbani et al (2011) using Nox1
-/-
 mice is the only study so far to have 
utilized any strain of Nox knockout mice in the study of tumor angiogenesis (64). 
Implantation of tumorigenic B16F0 melanoma cells subcutaneously in wild-type mice 
resulted in vascularised tumors after 10 days (64). In Nox1
-/-
 mice, the tumors that had 
developed were smaller and significantly less vascularised. This reduction in angiogenesis 
was associated with a reduction in expression of several genes, including VEGF, MMP-2 and 
MMP-9, and a reduction in NF-k activity.  
Although there is no in vivo evidence yet that Nox2 promotes tumor angiogenesis 
from the use of Nox2-deficient or -transgenic mice, there is certainly substantial evidence 
implicating Nox2 in ischemia reperfusion-dependent angiogenesis. Studies utilizing sponge 
implant assays demonstrate that VEGF-induced angiogenesis is significantly reduced in wild-
type mice treated with the antioxidant N-acetylcysteine (26) and also in untreated Nox2
-/-
 
mice, suggesting that ROS derived from Nox2 activity play an important role in angiogenesis 
Page 19 of 57 
A
nt
io
xi
da
nt
s &
 R
ed
ox
 S
ig
na
lin
g
N
A
D
PH
 O
X
ID
A
SE
S 
A
S 
RE
G
U
LA
TO
RS
 O
F 
TU
M
O
R 
A
N
G
IO
G
EN
ES
IS
: C
U
RR
EN
T 
A
N
D
 E
M
ER
G
IN
G
 C
O
N
CE
PT
S.
 (d
oi:
 10
.10
89
/ar
s.2
01
1.4
48
9)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
20 
 20 
in vivo (190). Also, neovascularization was significantly impaired in Nox2
-/-
 mice as 
compared with wild-type mice in an ischemic hindlimb model of angiogenesis (183, 187). To 
date, only one study has reported a role of Nox4 in the endothelial response to tumors in vivo 
(19). Bhandarkar et al (19) used a model of human hemangioma to implicate a link between 
Nox4 and tumorigenic angiogenesis. The role of Nox4 has been established in alternative 
models of angiogenesis, such as that occurring following hypoxia. Hypoxia is associated with 
upregulation of Nox4 in the endothelium, and promotion of the angiogenic process including 
endothelial proliferation, migration, and tube formation (34). Importantly, endothelial-specific 
Nox4 overexpression in vivo led to enhanced angiogenesis in response to hypoxia. Clearly, 
there is a huge knowledge gap in our understanding of the regulation of tumor angiogenesis in 
vivo and future studies should utilize mice with cell-specific inhibition of Nox oxidases.  
 
EMERGING CONCEPTS  
NADPH oxidase and lymphangiogenesis? 
Lymphangiogenesis is observed in many physiological and pathological settings, 
including embryonic development, tissue regeneration, wound healing and certain cancers. 
Similar to angiogenesis, we (208) and others (48, 72) have found that the VEGF family 
regulates lymphangiogenesis via VEGFR-2/VEGFR-3 homodimers or VEGFR-2-VEGFR-3 
heterodimers. The presence of VEGFR-3 correlates with lymph node metastasis in many solid 
tumors, including prostate (207, 209), small (22) and non-small lung carcinoma, leukemia 
(45), skin (124), gastric (168) and breast carcinoma (198). As many of the VEGF receptor 
signaling pathways activated by VEGF-A in endothelial cells, including MAPK, Src and 
PI3K/Akt, are similarly activated in lymphatic endothelial cells (101, 125, 133), it is likely 
that ROS may play a role in the regulation of lymphatic vessels. Hypoxia was shown to 
increase the expression levels of transcripts encoding VEGF-C, VEGF-D, as well as their 
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receptor VEGFR-3 in endothelial cells (141). Furthermore, Schoppmann et al (2006) showed 
that HIF-1 correlates with VEGF-C expression and lymphangiogenesis in breast cancer (162). 
Tumors with high levels of HIF-1 expression had a significantly increased amount of tumor-
associated lymphangiogenesis.  Indeed, HIF-1 may be a key factor regulating tumor-induced 
lymphangiogenesis as inflammation and VEGF-C-expressing inflammatory cells have both 
been shown to play a crucial role in tumor-associated lymphangiogenesis (33, 161). Irigoyen 
et al (2007) performed genome-wide analysis of hypoxia-dependent regulation of gene 
expression in lymphatic endothelial cells and found that in a low oxygen environment Nox4 
levels were increased (by 2-fold), along with other oxidative stress genes such as SOD2 (2.7-
fold) and ARG2 (3-fold) (87). The study did not analyse or report expression of any other 
NADPH oxidase family members. We speculate that lymphatic endothelial cells are likely to 
be regulated via NADPH oxidases akin to the observations in blood vessel endothelial cells.  
 
Are immune cell NADPH oxidases perpetrators of chronic inflammation-induced 
angiogenesis? 
There is a growing appreciation that inflammation plays a central role in angiogenesis 
and in re-vascularization in many cancers (33, 127). As a consequence, Mantovani and 
colleagues (2010) have recently suggested that inflammation should be recognized as an 
important hallmark of cancer (128). Epidemiological data supports this hypothesis (for review 
see (128)) identifying an association between inflammation and cancer initiation. For example, 
in humans, persistent inflammation caused by microbial infections such as Helicobacter 
pylori are associated with gastric cancer, colonization with the bacterium Haemophilus 
influenzae may lead to increased lung cancer risk and, via unknown pathogens, prostatitis is 
associated with prostate cancer. Key features of cancer-related inflammation include the 
infiltration of inflammatory cells such as macrophages and T cells, particularly T regulatory 
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cells (33, 55, 127). Animal and clinical studies provide strong evidence that tumor-associated 
macrophages promote tumorigenesis. Meta-analyses demonstrate that in over 80% of such 
studies there is a correlation between macrophage density and poor patient prognosis (21). For 
example, there is a strong association between poor survival and increased macrophage 
density in breast, prostate, thyroid, lung and liver cancers (for review see (112, 113, 153)). 
Macrophages are central to many immune responses and are immunoregulatory cells 
within the tumor. Macrophages are a dynamic and heterogeneous type of inflammatory cell, 
which show remarkable plasticity and exist in a number of phenotypically distinct states 
governed by stimuli within their immediate environment. Macrophages are now generally 
classified broadly into two categories, i.e. the ‘classically activated’ M1 macrophages and the 
so-called ‘alternatively activated’ M2 macrophages, based on their respective profiles of 
cytokine production, gene expression and cell surface markers (17, 129). The M1 
macrophages secrete pro-inflammatory mediators, including interleukin (IL)-1, IL-18, TNF-
 and IL-6, and express genes such as iNOS. Importantly, M1 macrophages are powerful 
generators of ROS such as superoxide, nitric oxide and peroxynitrite. The M2 macrophages in 
contrast, produce anti-inflammatory cytokines such as IL-10 and release angiogenic factors 
such as VEGF and TGF-.  
The initiation and progression of angiogenesis, and re-vascularization following 
VEGF inhibition can be the result of the infiltration/recruitment of macrophages to the tumor 
(32). The persistent recruitment of monocytes/macrophages in the tumor microenvironment 
activates them to release ROS and a wide variety of growth factors and cytokines including 
TGF- and VEGF, all of which exacerbate the mutagenic environment, and in doing so 
stimulate angiogenesis (32). Thus, it is conceivable that angiogenesis and tumor progression 
could be promoted by ROS generated by macrophages (Figure 3). In actuality, NADPH 
oxidase was first identified in inflammatory cells, such as macrophages and neutrophils, as 
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the enzyme responsible for the respiratory burst essential for the microbicidal function of 
these cells (10, 159). The NADPH oxidase complex here consists solely of Nox2 and on a 
molar basis these cells generate by far the most superoxide of all mammalian cells. Thus, it 
would not be surprising if macrophage Nox2 oxidase plays a key role in tumor angiogenesis. 
 
Does NADPH oxidase regulate immunosuppressor cells such as Tregs?  
CD8
+
 and CD4
+
 T lymphocyte subsets that infiltrate the tumor are a crucial component of the 
adaptive immune system that mounts an anti-tumor response. They are present in high 
numbers in solid tumors and their presence correlates with a better prognosis in several types 
of cancers including ovarian, pancreatic, breast and prostate cancers. This is particularly the 
case for cytotoxic CD8
+
 T lymphocytes that are generally considered to be tumorlytic. The 
role of CD4
+
 T cells, however, is more controversial. In particular, an increased abundance of 
a subset of CD4
+ 
T cells that co-express CD25 and the transcription factor FoxP3
+
, (otherwise 
known as regulatory T cells or Tregs) in the circulation and in the tumors of patients with 
ovarian cancer, gastrointestinal malignancies, breast cancer, pancreatic cancer and prostate 
cancer is predictive of a poor survival (36). 
Tregs are immunosuppressor cells, which play an essential role in controlling immune 
responses to either self or non-self antigens. They are considered to be associated with poor 
prognosis because they suppress CD8
+
 and CD4
+
 effector T cell proliferation and function to 
thereby limit their anti-tumor effects. Despite the well-known immunosuppressive function of 
Tregs, the mechanisms by which they achieve this are likely to be numerous, and are still 
unclear. The best understood pathway involves the release of TGF- and IL-10, both of which 
possess immunosuppressive effects. Given the inherent redox sensitivity of T cells, a recent 
study hypothesized that ROS may mediate the direct suppression of effector T cells by Tregs 
(52). Indeed, Tregs from p47phox
-/-
 mice have a reduced capacity to suppress effector T cells 
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compared to that of wild-type Tregs (52). Moreover, effector T cells from p47phox
-/-
 mice 
were significantly less sensitive than wild-type effector T cells to suppression by exogenous 
TGF-β (52). In addition, Nox2 oxidase may regulate the differentiation of Treg and effector T 
cells both in vitro and in vivo (111). Lee et al (2011) showed that Nox2 deficiency decreased 
the development of Tregs, but significantly promoted development of T effector cells such as 
Th1, Th2 and Th17 cells (111). Finally the activation of Tregs may be partially attributed to 
the actions of Nox2 expressed in macrophages (102). In vitro, macrophage-derived ROS 
induce Tregs, and this is suppressed by an NADPH-oxidase inhibitor (102). This finding was 
confirmed genetically, using macrophages from patients with CGD who have mutations in 
Nox2 or its key regulatory subunits resulting in either reduced expression or activity of the 
oxidase (102). Thus, CGD macrophages with mutated p47phox or Nox2 displayed reduced 
capacity for Treg induction and T cell suppression. Overall, it appears that Nox2 derived ROS 
may represent a potentially new target for therapeutic modulation of macrophage and Treg 
function (Figure 3), particularly in cancers that possess a strong inflammatory-based etiology. 
  
ANTIOXIDANTS IN THE TREATMENT OF CANCER  
 There has been much interest in the use of antioxidants in the treatment of cancer 
given its potential to enhance treatment efficacy and/or reduce treatment side effects. While 
the diversity of agents and treatment paradigms investigated have resulted in a lack of clear 
evidence that such an approach will be beneficial, several lines of evidence suggest that this is 
an area that is worthy of further attention. With particular regards to angiogenesis and the 
signaling pathways already described in this review, it has been shown that antioxidants 
vitamins C and E reduce vascular VEGF and VEGFR-2 expression in apolipoprotein-E 
deficient mice (140). The thiol antioxidant N-acetylcysteine (NAC) inhibited endothelial 
invasion and sarcoma-induced angiogenesis in vivo (as well as inhibiting tumor take and 
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invasion and metastasis) (26). Similarly, pigment epithelium-derived factor, which has 
antioxidant properties, has been shown to inhibit angiogenesis and melanoma growth (2). 
HMG-CoA reductase inhibitors, statins, which have been shown to inhibit Rac1 activity (109) 
can block angiogenesis in vivo (196). The flavones and catechins are powerful flavonoids that 
can protect the body against reactive oxygen species. As dietary antioxidants, flavonoids have 
been associated with a lower incidence of carcinogenesis (41). Some flavonoids, such as 
fisetin, apigenin, and luteolin, are potent inhibitors of both tumor and endothelial cell 
proliferation (57), and suppress in vitro angiogenesis. While further research is required to 
determine the role for antioxidants in the management of cancer, it is conceivable that 
targeting NADPH oxidases and downstream signaling pathways may be a useful tool once 
suitable reagents are developed. 
 
PHARMACOLOGICAL INHIBITORS OF NADPH OXIDASE  
The evidence presented thus far provides a strong rationale for the future use of 
pharmacological inhibitors of NADPH oxidase to suppress the oxidative stress that triggers 
somatic mutations and macromolecular modifications during cancer, as well as the abnormal 
and persistent cell signaling pathways that underpin cell proliferation and apoptosis during 
angiogenesis. Currently, there are a number of inhibitors of NADPH oxidase displaying 
varying degrees of selectivity for the specific Nox isoforms. These drugs have been 
comprehensively reviewed recently (50, 165) and are provided in tabulated form in this 
review (Table 1). Despite the accumulating evidence that provides the rationale for 
pharmacological blockade of NADPH oxidase during cancer, currently there are very few 
studies that have tested such compounds using in vivo animal models. In order to inhibit Nox4 
function pharmacologically in vivo, derivatives of the compound called fulvene, namely 
fulvene-5 have been used (19). To determine whether fulvene-5–induced loss of Nox4 
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demonstrated antitumorigenicity, mice were treated with fulvene-5 or vehicle control for 2 
weeks, and tumor growth as well as tumor burden were analyzed thereafter. Tumor growth in 
mice treated with fulvene-5 was significantly reduced compared with that in vehicle control 
treated mice (19). Administration of plumbagin, which is generally considered an inhibitor of 
Nox4-dependent superoxide production, following ectopic implantation of hormone-
refractory DU145 prostate cancer cells delayed tumor growth by 3 weeks and reduced both 
tumor weight and volume by 90% (9). Interestingly, cessation of plumbagin treatment for as 
long as 4 weeks did not result in progression of tumor growth. Although plumbagin has been 
touted as being a Nox4 specific inhibitor (53, 158), at concentrations as low as 5 micromol/L 
it was found to inhibit the expression of protein kinase C epsilon (PKC epsilon), 
phosphatidylinositol 3-kinase, phosphorylated AKT, phosphorylated janus-activated kinase-2, 
and phosphorylated signal transducer and activator of transcription 3 (Stat3) in both cultured 
prostate cancer cells and DU145 xenografts (9). These other actions are likely to have 
significant effects of tumor growth that are independent of Nox4. 
 
CONCLUSIONS AND PERSPECTIVES 
This review has summarized key current concepts and has touched upon some 
emerging ones regarding Nox signaling, as it pertains to angiogenesis in cancer. It has also 
highlighted the significant shortcomings in our current knowledge of this aspect of Nox 
signaling. As a consequence, substantial work remains to be performed to drive this exciting 
field forward. Indeed, future studies will need to carefully define: (1) stromal cell (i.e. 
endothelial cell)- and immune cell (macrophages, Tregs)- specific roles of Nox2 and other 
ROS generating enzymes including Nox1, Nox4, Duox1 and Duox2; (2) the activation 
mechanisms of NADPH oxidase by various (lymph)angiogenesis factors; and (3) molecular 
targets of NADPH oxidase-derived ROS in signaling pathways involved in 
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(lymph)angiogenic switch in different types of endothelial and cancer cells and (4) the X-ray 
crystal structures of catalytic (i.e. Nox) subunits and regulatory (i.e. p47phox, p67phox) 
subunits and their key binding sites to facilitate the development of more specific inhibitors of 
these enzyme complexes. The development of specific inhibitors of NADPH oxidases and 
redox signaling components (kinase, transcription factors and genes) could provide useful 
therapeutic strategies for treatment of various (lymph)angiogenesis-dependent pathologies 
during cancer. 
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LIST OF ABBREVIATIONS 
Angiopoietin-like-protein 4 (ANGPTL4) 
Chronic granulomatous disease (CGD) 
Extracellular regulated kinase (ERK) 
Flavin adenine dinucleotide (FAD) 
Hydrogen peroxide (H2O2) 
mitogen activated protein kinase (MAPK) 
Nitric oxide (NO) 
Peroxynitrite (OONO-) 
Phosphatidylinositol-3 kinase (PI3-K) 
polymerase -interacting protein 2 (POLDIP2) 
Reactive oxygen species (ROS) 
Vascular endothelial growth factor (VEGF) 
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FIGURE LEGENDS 
Figure 1. Pathways for the formation of ROS and selected biological effects.  
 
Figure 2. Schematic diagram showing subunit composition of the 5 NADPH oxidase 
isoforms and their subcellular localization.  
 
Figure 3. Schematic diagram depicting cellular localization of Nox within the tumor 
microenvironment as well as established and possible signaling pathways that underpin 
angiogenic responses. Growth factors such as vascular endothelial growth factor (VEGF), 
fibroblast growth factor (FGF) and transforming growth factor-TGF-released by tumor 
cells and macrophages activate specific receptors on endothelial cells, which in turn leads to 
Nox recruitment and activation, ROS production, and proliferation and migration via 
extracellular signal-regulated kinase (ERK), PI3-K/protein kinase B (AKT) and Src pathways. 
Also, ROS produced within tumor cells influences their proliferation and the expression of 
VEGF-A. Moreover, macrophage Nox2-derived ROS may possess paracrine effects on T 
lymphocyte subsets such as CD4
+
CD25
+
FoxP3
+
 regulatory T cells (Tregs) to promote their 
development and subsequent suppressive effects. The suppression of CD8
+
 and CD4
+
 effector 
T cells by Tregs may be partially due to Nox2-derived ROS. (VEGF, vascular endothelial 
growth factor; FGF, fibroblast growth factors; TGF-, transforming growth factor-; ERK, 
extracellular-signal-regulated kinase; Akt, protein kinase b; PI3K, phosphoinositide-3-kinase).  
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